DOCSLIB.ORG

Pathophysiological Basis of Endometriosis-Linked Stress Associated with Pain and Infertility: a Conceptual Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathophysiological Basis of Endometriosis-Linked Stress Associated with Pain and Infertility: a Conceptual Review reproductive medicine Review Pathophysiological Basis of Endometriosis-Linked Stress Associated with Pain and Infertility: A Conceptual Review Debabrata Ghosh 1,* , Ludmila Filaretova 2, Juhi Bharti 3, Kallol K. Roy 3, Jai B. Sharma 3 1, and Jayasree Sengupta y 1 Laboratory of Molecular Physiology, Department of Physiology, All India Institute of Medical Sciences, New Delhi 110029, India; [email protected] 2 Laboratory of Experimental Endocrinology, Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 199034, Russia; fi[email protected] 3 Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi 110029, India; [email protected] (J.B.); [email protected] (K.K.R.); [email protected] (J.B.S.) * Correspondence: [email protected] Presently retired. y Received: 7 May 2020; Accepted: 3 June 2020; Published: 8 June 2020 Abstract: Women with endometriosis are often under stress due to the associated pain, infertility, inflammation-related and other comorbidities including cancer. Additionally, these women are also under stress due to taboos, myths, inter-personal troubles surrounding infertility and pain of the disease as well as due to frequent incidences of missed diagnosis and treatment recurrence. Often these women suffer from frustration and loss of valuable time in the prime phase of life. All these complexities integral to endometriosis posit a hyperstructure of integrative stress physiology with overt differentials in effective allostatic state in women with disease compared with disease-free women. In the present review, we aim to critically examine various aspects of pathophysiological basis of stress surrounding endometriosis with special emphasis on pain and subfertility that are known to affect the overall health and quality of life of women with the disease and promising pathophysiological basis for its effective management. Keywords: allostasis; comorbidity; endometriosis; infertility; inflammation; pain 1. Introduction Endometriosis occurs due to the growth of endometrium-like tissue outside the uterus. As summarized in Figure1, it is a complex disorder that is influenced by genetic, epigenetic and environmental factors [1–5]. Endometrial cells, stem cells and bone marrow cells with genetic and epigenetic defects after implantation and metaplasia within an abnormal environment of the peritoneal cavity progress to form the typical ectopic lesions in ovary, peritoneum and rectovaginal compartments [6,7]. Endometriosis is associated with chronic inflammatory disorder state along with pelvic pain affecting 10–15% women during their reproductive years, as well as with primary infertility in 50% women [8–10]. Reprod. Med. 2020, 1, 32–61; doi:10.3390/reprodmed1010004 www.mdpi.com/journal/reprodmed Reprod. Med. 2020, 1, FOR PEER REVIEW 2 Reprod. Med. 2020, 1 33 Reprod. Med. 2020, 1, FOR PEER REVIEW 2 FigureFigureFigure 1.1. A 1. simplifiedsimplifiedA simplified schema schema of of histogenesis histogenesis of endometriosis endometriosis involving involving several several predisposing, predisposing,predisposing, triggeringtriggeringtriggering andand and progressionprogression progression factors.factors. factors. It ItIt isis notablenotable th thatthatat dysregulated dysregulated allostatic allostatic load load at the at local thethe locallocaland andand systemicsystemicsystemic levels levels plays plays plays critical critical critical role role role in in the the the inducement inducement inducement ofof ectopic ofectopic ectopic lesions lesions lesions of ofendometriosis. endometriosis. of endometriosis. Adapted Adapted from Adapted from fromGhoshGhosh Ghosh et al.et et [11].al. al. [11]. [ 11(A]. )( A (ALaparoscopic) )Laparoscopic Laparoscopic viewview view ofof ofright right ovarianovarian ovarian endometrioma endometrioma endometrioma with with with severe severe adhesion adhesionadhesion obliterating the pouch of Douglas. (B) Low magnification histopathological features of an ovarian obliteratingobliterating thethe pouchpouch ofof Douglas.Douglas. (B)) LowLow magnificationmagnification histopathologicalhistopathological features ofof anan ovarianovarian endometriotic cyst with circumscribed stromal nodule and epithelial lining seen (B). endometrioticendometriotic cystcyst withwith circumscribedcircumscribed stromalstromal nodulenodule andand epithelialepithelial lininglining seenseen (B(B).). Endometriosis impairs the quality of life due to chronic and severe acyclic pelvic pain with EndometriosisEndometriosis impairs the quality of life duedue toto chronicchronic andand severesevere acyclicacyclic pelvicpelvic painpain withwith associated dysmenorrhea, dyspareunia, gastrointestinal problems, fatigue and headaches [12,13]. associatedassociatedBeside dysmenorrhea,pelvicdysmenorrhea, pain, endometriosis dyspareunia, is associated gastrointestinalgastrointe with stinalsubfertility. problems, The fecundity fatigue rate and for headaches a couple with [12,13]. [12 ,13]. BesideBesidethe pelvic woman pain, pain, partner endometriosis endometriosis having endometriosis is is associated associated is withreduced with subfertility. subfertility.to 2–10%, The as The comparedfecundity fecundity to rate 15–20% ratefor a for coupleamong a couple with withthe womanendometriosis-free the woman partner partner having controls having endometriosis [14]. endometriosis This is true is for re is ducedthe reduced Caucasian to to2–10%, 2–10%, population, as as compared compared and more to to so15–20% for Asian amongamong endometriosis-freeendometriosis-freewomen [15,16]. controls [[14].14]. This is true for the CaucasianCaucasian population,population, and more soso forfor AsianAsian womenwomen [[15,16].15Stress,16]. from endometriosis-associated pain and infertility, although well perceived, appears StressenigmaticStress fromfrom due endometriosis-associatedendometriosis-associated to underlying multifactorial painpain comp andandlexities. infertility,infertility, Women althoughalthoughwith endometriosis wellwell perceived,perceived, often suffer appearsappears enigmaticenigmaticfrom several duedue to to inflammation-linked underlying underlying multifactorial multifactorial and other complexities. compcomorbiditieslexities. Women (see Women Figure with with2 endometriosis for details).endometriosis often often suffer suffer from severalfrom several inflammation-linked inflammation-linked and other and comorbiditiesother comorbidities (see Figure (see Figure2 for details). 2 for details). Figure 2. The comorbidities associated with endometriosis. The incidence of developing several comorbidities was significantly higher among women with endometriosis as compared to women without endometriosis. For details, see references [17–21]. FigureFigure 2.2. The comorbiditiescomorbidities associatedassociated withwith endometriosis.endometriosis. The incidence of developingdeveloping severalseveral comorbiditiescomorbidities waswas significantlysignificantly higherhigher amongamong womenwomen withwith endometriosisendometriosis asas comparedcompared toto womenwomen withoutwithout endometriosis.endometriosis. ForFor details,details, seesee referencesreferences [[17–21].17–21]. Reprod. Med. 2020, 1 34 Reprod. Med. 2020, 1, FOR PEER REVIEW 3 AsAs aa result,result, womenwomen withwith endometriosisendometriosis areare oftenoften surroundedsurrounded byby taboos,taboos, myths,myths, scourgescourge ofof subfertility,subfertility, painpain ofof diseasedisease andand missedmissed diagnosisdiagnosis andand treatmenttreatment [[22].22]. DelaysDelays inin thethe diagnosisdiagnosis andand initiationinitiation ofof treatmenttreatment forfor thethe diseasedisease inin factfact occuroccur duedue toto thesethese counterproductivecounterproductive factorsfactors operativeoperative bothboth atat the the individual individual patient patient level level and and at the at medicalthe medical level resultinglevel resulting in frustration in frustration and loss and of valuable loss of timevaluable in the time prime in phasethe prime of life phase of the patientof life of [22 the–25 ].patient While [22–25]. endometriosis While isendometriosis generally considered is generally to be benign,considered the moderateto be benign, probability the moderate that endometriosis probability maythat beendometriosis associated with may incidences be associated of ovarian with andincidences extra-ovarian of ovarian cancers and extra-ovarian adds to the mounting cancers adds stress to on the the mounting women astressffected on by the the women disease affected [6,11]. Aby dramatic the disease image [6,11]. hoisted A dramatic by the World image Endometriosis hoisted by the Research World Endometriosis Foundation attempts Research to encapsulateFoundation theattempts stress ofto endometriosisencapsulate the that stress affects of an endometrio estimated 200sis millionthat affects women an worldwideestimated (see200 Figuremillion3 ).women In the presentworldwide narrative (see Figure review, 3). we In aimthe present to examine narrative various re aspectsview, we of aim stress to physiologyexamine various during aspects endometriosis of stress withphysiology special during emphasis endometriosis on pain and with infertility special that emphas can aisffect on thepain overall and infertility health and that quality can affect of life the of womenoverall health with the and disease. quality At of the life end, of women a brief discussionwith the disease. on the At future the courseend, a brief of targeted discussion
Load more

Recommended publications
  • Hormones and Breeding
    IN-DEPTH: REPRODUCTIVE ENDOCRINOLOGY Hormones and Breeding Carlos R.F. Pinto, MedVet, PhD, Diplomate ACT Author’s address: Theriogenology and Reproductive Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210; e-mail: [email protected]. © 2013 AAEP. 1. Introduction affected by PGF treatment to induce estrus. In The administration of hormones to mares during other words, once luteolysis takes place, whether breeding management is an essential tool for equine induced by PGF treatment or occurring naturally, practitioners. Proper and timely administration of the events that follow (estrus behavior, ovulation specific hormones to broodmares may be targeted to and fertility) are essentially similar or minimally prevent reproductive disorders, to serve as an aid to affected (eg, decreased signs of behavioral estrus). treating reproductive disorders or hormonal imbal- Duration of diestrus and interovulatory intervals ances, and to optimize reproductive efficiency, for are shortened after PGF administration.1 The example, through induction of estrus or ovulation. equine corpus luteum (CL) is responsive to PGF These hormones, when administered exogenously, luteolytic effects any day after ovulation; however, act to control the duration and onset of the different only CL Ͼ5 days are responsive to one bolus injec- stages of the estrous cycle, specifically by affecting tion of PGF.2,3 Luteolysis or antiluteogenesis can duration of luteal function, hastening ovulation es- be reliably achieved in CL Ͻ5 days only if multiple pecially for timed artificial insemination and stimu- PGF treatments are administered. For that rea- lating myometrial activity in mares susceptible to or son, it became a widespread practice to administer showing delayed uterine clearance.
    [Show full text]
  • Development of Psychophysiological Motoric Reactivity Is Influenced By
    Development of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing hormone action - Results of an ovine model Neil P. Evans, Jane Robinson J.E., Hans Erhard, Erik Ropstad, Lynne M. Fleming, Ira Ronit Hebold Haraldsen To cite this version: Neil P. Evans, Jane Robinson J.E., Hans Erhard, Erik Ropstad, Lynne M. Fleming, et al.. Develop- ment of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing hormone action - Results of an ovine model. Psychoneuroendocrinology, El- sevier, 2012, 37 (11), pp.1876-1884. 10.1016/j.psyneuen.2012.03.020. hal-01186791 HAL Id: hal-01186791 https://hal.archives-ouvertes.fr/hal-01186791 Submitted on 29 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. + Models PNEC-2163; No. of Pages 9 Psychoneuroendocrinology (2012) xxx, xxx—xxx Available online at www.sciencedirect.com j ournal homepage: www.elsevier.com/locate/psyneuen Development of psychophysiological motoric reactivity is influenced by peripubertal pharmacological inhibition of gonadotropin releasing § hormone action — Results of an ovine model a, a b c Neil P. Evans *, Jane E. Robinson , Hans W. Erhard , Erik Ropstad , a d Lynne M.
    [Show full text]
  • III IIII USO05721278A United States Patent (19) 11) Patent Number: 5,721,278 Garfield Et Al
    III IIII USO05721278A United States Patent (19) 11) Patent Number: 5,721,278 Garfield et al. 45) Date of Patent: Feb. 24, 1998 54 OWULATON CONTROL BY REGULATING 58) Field of Search ............................ 514/15, 121, 651, NTRC OXDE LEVELS 514/652,561, 841, 843, 648 Inventors: Robert E. Garfield, Friendswood; 56 References Cited Chandrasekhar Yallampalli, Houston, U.S. PATENT DOCUMENTS both of Tex. 4,338,305 7/1982 Corbin ................................... 424/177 73 Assignee: Board of Regents, The University of 4,851,385 7/1989 Rueske ..................................... 514/15 Texas System, Austin,Tex. 5,470,847 11/1995 Garfield et al. ......................... 514/171. Primary Examiner. Theodore J. Criares 21 Appl. No.: 477,187 Attorney, Agent, or Firm-Arnold, White & Durkee 22 Filed: Jun. 7, 1995 57 ABSTRACT Inhibition of ovulation in a female may be achieved by Related U.S. Application Data administering a nitric oxide synthase inhibitor, alone or in 62 Division of Ser. No. 165,309, Dec. 10, 1993, Pat. No. combination with one or more of a progestin, an estrogen, 5,470,847. and an LH-RH antagonist, thereby preventing conception. The stimulation of ovulation in a female may be achieved by 51) Int. Cl. ......... A61K 31/195; A61K 31/135: administering a nitric oxide source, optionally in further A61K 31/56 combination with one or more of clomiphene, a 52 U.S.C. ....................... 514/652; 514/171; 514/561; gonadotropin, and an LH-RH agonist. 514/563; 514/651; 514/565; 514/841; 514/843; 514/648 4 Claims, 1 Drawing Sheet U.S. Patent Feb. 24, 1998 5,721,278 HypothalamuS Anterior Pituitary Gland ProgesterOne Estrogen / \ CorpOra OVa lutea \(es j \s 63 O Graafian follicle Follicular Ovulatory Luteal PaSe Phase Phase FIG.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Download Article As
    FOCUS > EQUINE FOCUS < OVINE FOCUS > EQUINE Inducing timed ovulation in the mare Susan Salter BSc Hons BVM&S MRCVS and Jonathon Pycock BVetMed PhD DESM MRCVS compare and contrast various ovulating agents used to induce ovulation in mares at breeding, highlighting the advantages and disadvantages, effi cacy and welfare implications associated with each Weatherbys documented 14,747 active thoroughbred hCG was used on subsequent cycles. They also showed broodmares in Ireland in 2019, almost twice as many as that younger mares were more likely to ovulate within 48 the UK which recorded 8,571. Ireland is the third biggest hours than older mares when given hCG. Repeated use of producer of thoroughbreds in the world after Australia and hCG is, therefore, associated with decreased reliability in the USA.1 inducing timed ovulation and e icacy declines significantly In addition, it is estimated that there are around 15,000 active with increased mare age making it unreliable for use in breeders in the sport horse sector. 2 In order to maximise the older mares.3 In Ireland, hCG is still used since the deslorelin e iciency of breeding, it is essential that timing of ovulation implant has labour, cost, welfare and safety implications. can be manipulated e ectively. It is also imperative that attempts to manipulate timing of ovulation are not associated DESLORELIN ACETATE – THE IMPLANT AND THE with subsequent delays in return to oestrus. The current INJECTABLE Covid-19 crisis presents additional challenges and pressures Deslorelin is a gonadotrophin releasing hormone (GnRH) of balancing the economic imperative to continue equine receptor agonist.
    [Show full text]
  • (CERCA), Ecole Nationale Vétérinaire D'alfort
    Rev. Bras. Reprod. Anim., Belo Horizonte, v.35, n.2, p.210-216, abr./jun. 2011. Disponível em ww.cbra.org.br. The use of GnRH agonists implants in bitches and queens Utilização de implantes de agonistas do GnRH em cadelas e gatas A. Fontbonne1, E. Fontaine Centre d’Etude en Reproduction des Carnivores (CERCA), Alfort Veterinary College, Paris, France. 1Corresponding author: [email protected] Abstract GnRH (gonadotrophin releasing hormone) is a key hormone of reproductive function in mammals; agonist forms have been largely developed, and data concerning their use in small animal reproduction are now abundant. GnRH agonists act by a two-step mechanism. First, their agonist properties on the pituitary will cause marked LH (luteinizing hormone) and FSH (follicle-stimulating hormone) secretion into the bloodstream, accompanied by an increase in the concentrations of sex steroid hormones. Then, in case of constant administration, GnRH agonists will lead to pituitary desensitization, and FSH and LH levels will collapse. These two effects have been widely documented, and these compounds have many potential benefits in a clinical context, capitalizing both on their stimulating and sterilizing effects. Keywords: bitch, deslorelin, GnRH agonists, queen. Resumo O hormônio liberador de gonadotrofinas (GnRH) é um hormônio chave na função reprodutiva dos mamíferos. Formas agonistas têm sido amplamente desenvolvidas e atualmente existem muitas informações sobre sua utilização na reprodução de pequenos animais. Os agonistas do GnRH atuam por meio de um mecanismo que envolve duas etapas. Inicialmente, suas propriedades agonistas irão causar secreção marcante de hormônio luteinizante (LH) e folículo-estimulante (FSH) pela hipófise, acompanhado pelo aumento das concentrações dos hormônios esteróides sexuais.
    [Show full text]
  • Annual Report
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2010 ! TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 333-150937 Curaxis Pharmaceutical Corporation (Exact name of registrant as specified in its charter) Nevada 26-1919261 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation or Organization) 51 Berkshire Street Swampscott, MA, 01907 (Address of principal executive offices) (919) 313-4930 (Registrant’s telephone number, including area code) Securities registered under Section 12(b) of the Exchange Act: None Securities registered under Section 12(g) of the Exchange Act: Common Stock, par value $0.0001 per share Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ! No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ! No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No ! Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Use of a Gonadotropin Releasing Hormone Agonist Implant
    Use of a Gonadotropin Releasing Hormone Agonist Implant Containing 4.7 mg Deslorelin for Medical Castration in Male Ferrets (Mustela putorius furo) Bulliot Christophe, DVM1 Mentré Véronique, DVM2 Berthelet Adeline, DVM3 Navarro Christelle, DVM4 Bidaud Alice, DVM4 1 Corresponding author: Clinique Vétérinaire Exotic Clinic, 38 rue Robert Cousin, 77176 Nandy, France. E-mail: [email protected] 2 Clinique Vétérinaire de la Patte d’Oie, 155 Bd Victor Bordier, 95370 Montigny les Cormeilles, France. E-mail: [email protected] 3 Clinique Vétérinaire Exotic Clinic, 38 rue Robert Cousin, 77176 Nandy, France. E-mail: [email protected] 4 Virbac, 13ème rue - LID, 06511 Carros, France. Conflict of interest: the study was funded by Virbac. KEY WORDS: Ferret, Deslorelin, tent, for medical castration. This study is the Gonadotropin, GnRH, medical castration first evaluation of a GnRH-agonist implant containing 4.7 mg deslorelin for medical ABSTRACT castration in male ferrets with an assessment Sterilization of ferrets (Mustela putorius of the duration of infertility over a 3-year furo) is a common practice. Male ferrets, follow-up. Twenty-nine intact male ferrets unlike females, don’t need castration for in rut were implanted and were used for medical reasons, but are frequently neutered tolerance evaluation. Infertility was assessed to prevent reproduction and reduce their in 27 ferrets by evaluating their testosterone musky odor and aggressive territorial behav- concentrations, testis size and musky odor. ior. The search for an alternative to surgical Our results indicated that infertility was in- castration is an important goal and challenge duced within 6 weeks post-implantation and in this species.
    [Show full text]
  • 2018 Summary of Major Modifications and Explanatory Notes
    SUMMARY OF MAJOR MODIFICATIONS AND EXPLANATORY NOTES 2018 PROHIBITED LIST Substances and methods prohibited at all times (In- and Out-of-Competition) Prohibited Substances S1 ANABOLIC AGENTS S3 BETA-2-AGONISTS • Dihydrotestosterone was renamed to its International • Dosing parameters of salbutamol were revised to make Non-proprietary Name (INN) (androstanolone). it clear that divided doses of salbutamol may not exceed 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one) 800 micrograms over any 12 hours (see figure). was added in S1.a as an example of exogenous anabolic steroid. Inhaled salbutamol – max. 1600 mcg over 24 hours But not to exceed 800 mcg over any 12 hours • LGD-4033 and RAD140 were added as further examples 0 12 24 of SARMs. Any 12 hour period: max. 800 mcg PEPTIDE HORMONES, GROWTH S2 FACTORS, RELATED SUBSTANCES 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg 200 mcg AND MIMETICS • For clarity and accuracy Section S2 was reorganized. • Tulobuterol was added as an example. • ARA290 was removed as an example in this section • The statement on the urinary thresholds was improved. because current literature suggests it does not meet inclusion criteria. • Deslorelin, goserelin, nafarelin and triptorelin were HORMONE AND METABOLIC added as examples of 2.1. S4 MODULATORS • Growth Hormone fragments were included in 2.3 with • Clomifene is now stated by its INN. AOD-9604 and hGH 176-191 added as examples; CJC-1293 was added as example of GHRH and • In the absence of an INN, the IUPAC name of GW1516, tabimorelin as a further example of GH secretagogue.
    [Show full text]
  • 2013 BCPS J.Pmd
    REVIEW ARTICLES Endometriosis - An Update LP BANUa, S TASNIMb Summary: relevant information. The study results showed that both Endometriosis is a common and important health problem medical and surgical treatments are almost equally effective of women. The prevalence of endometriosis is difficult to in pain management there is no evidence that medical determine. Diagnosis is often difficult and delayed due to treatment improves fertility. Surgical treatment is associated close similarity of symptoms of endometriosis with other with small but significant improvement in live birth rate. gynecological disorder. Optimum treatment involves a Newer non hormonal drugs are more selective with less combination of medical and surgical treatments tailored to metabolic side effects. Surgical treatment is invasive the patient’s needs and response. procedure and repeated surgery is associated with major complication. The objective of the study is to discuss the current updates Medical treatment is considered more effective in the long on diagnosis, treatment and the optimal role of different term management of endometriosis. options in the treatment of endometriosis. The article reviews different medical journals, medline and internet to get the (J Banagladesh Coll Phys Surg 2013; 31: 144-149) Introduction: Endometriosis run in families. The mode of inheritance Endometriosis is a chronic and recurrent disease is probably polygenic and multi factorial. Chromosome characterized by the presence and proliferation of no 10 q26 5, 6 is thought to carry the involved gene. functional endometrial glands and stroma outside the There is some defect in immune response to tissue injury uterine cavity. Around 10% of women of reproductive in women with endometriosis that fail to remove age are affected by endometriosis, suffer from chronic refluxed menstrual debris from the extra uterine site.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,309,689 B2 Trigg Et A]
    US007309689B2 (12) United States Patent (10) Patent N0.: US 7,309,689 B2 Trigg et a]. (45) Date of Patent: *Dec. 18, 2007 (54) SUSTAINED PEPTIDE-RELEASE 5,256,649 A 10/1993 Le Fur et al. FORMULATION 5,340,585 A 8/1994 Pike 5,372,996 A 12/1994 Labrie ....................... .. 514/15 (75) Inventors: Timothy Elliot Trigg, WarraWee (AU); 5,573,781 A 11/1996 Brown et a1. ............. .. 424/484 John Desmond Walsh, Curl Curl (AU); 5,925,619 A 7/1999 Walsh Paul Adam Schober, Beacon Hill (AU) 6,337,318 B1 1/2002 Trigg et al. ................. .. 514/15 FOREIGN PATENT DOCUMENTS (73) Assignee: Peptech Limited, North Ryde (AU) AU A-41059/85 10/1985 ( * ) Notice: Subject to any disclaimer, the term of this EP 0 158 277 10/1985 patent is extended or adjusted under 35 EP 0 254 693 1/1988 U.S.C. 154(b) by 268 days. EP 0 645 136 A2 3/1995 GB 2 052 258 1/1981 JP 62-192327 8/1987 This patent is subject to a terminal dis WO 86/04503 8/1986 claimer. WO 92/18107 10/1992 W0 WO 93/07833 4/1993 WO 92/15722 8/1993 (21) Appl. No.: 10/808,504 WO 96/34012 10/1996 (22) Filed: Mar. 25, 2004 W0 WO 97/00693 1/1997 (65) Prior Publication Data OTHER PUBLICATIONS US 2004/0180832 A1 Sep. 16, 2004 Liu et a1; “E?cects of PituitaryiTesticular Axis Suppression in Utero and during . ”, Journal ofEndocrinology and Related US. Application Data Metabolism, vol. 73, No.
    [Show full text]
  • Pharmacy Prior Authorization Guideline
    Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline Guideline Name Gonadotropins and Antigonadotropins: Bravelle (urofollitropin), Cetrotide (cetrorelix), chorionic gonadotropin, Ganirelix, Gonal-F (follitropin alfa), Follistim AQ (follitropin beta), Menopur (menotropin), Novarel (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), and Pregnyl (chorionic gonadotropin) 1 . Criteria Product Name: Bravelle, Cetrotide, generic chorionic gonadotropin, Ganirelix, Gonal-F, Gonal- F RFF, Menopur, Novarel, Ovidrel, Pregnyl Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s)* Guideline Type Prior Authorization Approval Criteria 1 - Patient has been approved for infertility services through a Harvard Pilgrim Health Care (HPHC) medical authorization^ Notes ^ The approval duration for formulary infertility medications (authorized by HPHC Pharmacy Benefit) will be approved 1 month prior to the date of the medical infertility services authorization (authorized by HPHC Medical Benefit) plus an additional 6 months unless specified otherwise on PA request (for a total of up to 7 months). *For approvals: Please approve at GPI List Name HPHCMEDIVF. **Some plans EXCLUDE gonadotropin products for infertility and claims will reject as Plan Exclusion: Plan excludes meds for infertility. Product Name: Follistim AQ Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s) Guideline Type Non-Formulary Approval Criteria 1 - Patient has
    [Show full text]